Bristol Discontinues Development Of Inhibitex Nuc, Will Take $1.8 Billion Hit

On Aug. 1, Bristol halted Phase II study of nucleoside polymerase inhibitor BMS-986094 due to a serious case of cardiac toxicity – the pharma since has revealed that the afflicted patient died and nine total have been hospitalized with heart and kidney problems.